AREVA, with support from AEC Partners*, signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) in Bethesda, Maryland (USA), to develop a new treatment to fight cancer.
As part of the agreement, AREVA will provide medical quality lead-212 to the NCI for the design of a new radiopharmaceutical drug in the near future.
Lead-212 was until today considered a very scarce radioactive element and is figuring in promising research on treatment for certain cancers for which the current arsenal of therapies has only limited results.
Michael McMurphy, President of AREVA Inc., offered the following comment: "AREVA is very proud to have approved and launched this innovative project several years ago and to contribute to progress in the field of nuclear medicine today by applying our know-how and technology. This important project is the direct result of AREVA's commitment to sustainable development."
* Since 1995, AEC Partners has served as strategic and financial advisor to the Healthcare Industry. Our customer base includes most world's leading pharmaceutical, medical devices and diagnostics companies as well as regulatory authorities, mid-size corporations, small startups and a large number of private equity firms. Our expertise covers strategy (organization, R&D and marketing), regulatory impact assessment, and acquisition, strategic due diligence, mergers and acquisitions including negotiation of licensing agreements. With offices in Paris and New York, our twenty-five strong team of seasoned multinational professionals have consulted throughout Western Europe, US and a certain number of developing countries.
6/11/2008